Cargando…
Treatment adherence and social functioning in patients diagnosed with schizophrenia and treated with antipsychotic depot medication
BACKGROUND AND AIM: Some of the most significant problems encountered in the treatment of schizophrenia are non-adherence to the treatment with oral neuroleptics and difficult recovery of social functioning, after its impairment by negative psychotic symptoms and the progression of the disease with...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iuliu Hatieganu University of Medicine and Pharmacy
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462419/ https://www.ncbi.nlm.nih.gov/pubmed/26528009 http://dx.doi.org/10.15386/cjmed-292 |
Sumario: | BACKGROUND AND AIM: Some of the most significant problems encountered in the treatment of schizophrenia are non-adherence to the treatment with oral neuroleptics and difficult recovery of social functioning, after its impairment by negative psychotic symptoms and the progression of the disease with episodes of remission and relapse. METHODS: This study comparatively assesses the parameters “social functioning” and “treatment adherence” in 34 outpatients diagnosed with schizophrenia at the Adult Psychiatry Clinic III and the Adult Mental Health Center of Cluj-Napoca, using the “Medication Adherence Rating Scale” (MARS) and the “Social Adaptation Self-evaluation Scale”. RESULTS: The two scales revealed that patients on depot medication tend to have better social functioning and social integration rates than patients for whom oral medication was prescribed. Despite the fact that most patients participating in the study had intellectual preoccupations and, to some extent, enjoyed working, 82% of them did not have a job. The percentage of those who did was higher in the cohort of patients on depot medication (63%) than in the cohort of patients for whom orally administered medication was prescribed (53%). CONCLUSIONS: Treatment adherence in patients with schizophrenia is thus significantly improved by depot medication, whereas treatment effectiveness and the frequency of adverse effects are similar for the two treatment options. |
---|